Literature DB >> 16530725

Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells.

Jian Liu1, Peter Schuff-Werner, Michael Steiner.   

Abstract

Interleukin 8 (IL-8) and vascular endothelial growth factor (VEGF) are two cytokines promoting prostate tumor growth and angiogenesis. The main coagulation protease thrombin may modulate the malignant phenotype of prostate cancer cells via its cellular receptor(s). We aimed to investigate the effects of thrombin on IL-8 and VEGF expression in DU 145 prostate cancer cells. Thrombin induced the expression and secretion of IL-8 and VEGF, with more pronounced effects on IL-8. Target-specific siRNA-induced protease-activated receptor 1 (PAR-1) knockdown completely neutralized thrombin-enhanced cytokine secretion, demonstrating the essential role of PAR-1. Inhibitors of either extracellular signal-regulating kinase (ERK) or phosphatidylinositol 3-kinase (PI3K) partly reversed the thrombin-induced cytokine expression, suggesting that both ERK and PI3K kinase pathways may be involved in IL-8 and VEGF expression. The results suggest that the thrombin/PAR-1 system upregulates cytokines in prostate cancer cells which in turn may contribute to the progression of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530725     DOI: 10.1016/j.bbrc.2006.02.136

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Proteinase-activated receptors in the lower urinary tract.

Authors:  James D Moffatt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-10       Impact factor: 3.000

2.  Protease activated receptor-1 mediates cytotoxicity during ischemia using in vivo and in vitro models.

Authors:  P S Rajput; P D Lyden; B Chen; J A Lamb; B Pereira; A Lamb; L Zhao; I-F Lei; J Bai
Journal:  Neuroscience       Date:  2014-09-28       Impact factor: 3.590

3.  Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma?

Authors:  Kunihiro Asanuma; Tomoki Nakamura; Takayuki Okamoto; Tomohito Hagi; Kouji Kita; Koichi Nakamura; Yumi Matsuyama; Keisuke Yoshida; Yumiko Asanuma; Akihiro Sudo
Journal:  BMC Cancer       Date:  2022-10-18       Impact factor: 4.638

Review 4.  Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management.

Authors:  E Donnellan; B Kevane; B R Healey Bird; F Ni Ainle
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

Review 5.  Inflammation and NF-κB Signaling in Prostate Cancer: Mechanisms and Clinical Implications.

Authors:  Jens Staal; Rudi Beyaert
Journal:  Cells       Date:  2018-08-29       Impact factor: 6.600

6.  Transcriptional Regulation of Thrombin-Induced Endothelial VEGF Induction and Proangiogenic Response.

Authors:  Rusan Catar; Guido Moll; Isa Hosp; Michele Simon; Christian Luecht; Hongfan Zhao; Dashan Wu; Lei Chen; Julian Kamhieh-Milz; Katarzyna Korybalska; Daniel Zickler; Janusz Witowski
Journal:  Cells       Date:  2021-04-15       Impact factor: 6.600

Review 7.  Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?

Authors:  Mark P Ward; Laura E Kane; Sharon A O'Toole; John J O'Leary; Lucy A Norris; Bashir M Mohamed; Tanya Kelly; Mark Bates; Andres Clarke; Nathan Brady; Cara M Martin; Robert D Brooks; Doug A Brooks; Stavros Selemidis; Sean Hanniffy; Eric P Dixon
Journal:  Mol Cancer       Date:  2021-03-31       Impact factor: 27.401

8.  Downregulation of protease activated receptor expression and cytokine production in P815 cells by RNA interference.

Authors:  Liya Qiao; Huiyun Zhang; Shandong Wu; Shaoheng He
Journal:  BMC Cell Biol       Date:  2009-09-07       Impact factor: 4.241

9.  Regulatory network of inflammation downstream of proteinase-activated receptors.

Authors:  Ricardo Saban; Michael R D'Andrea; Patricia Andrade-Gordon; Claudia K Derian; Igor Dozmorov; Michael A Ihnat; Robert E Hurst; Cindy Simpson; Marcia R Saban
Journal:  BMC Physiol       Date:  2007-03-30

10.  Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial.

Authors:  John Castle; Emma Blower; Nigel J Bundred; James R Harvey; Jecko Thachil; Andrea Marshall; Karina Cox; Silvia Cicconi; Chris Holcombe; Carlos Palmieri; Cliona C Kirwan
Journal:  Trials       Date:  2020-08-27       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.